Navigation Links
ProMIS Neurosciences Initiates Groundbreaking Cohort Study to Evaluate Prevalence of Different Amyloid Beta Prion Strains in Alzheimer’s Disease
Date:11/8/2016

ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced initiation of a Cohort Study to evaluate the prevalence of different strains of Amyloid beta (Aß) prions in patients with Alzheimer’s disease (AD). The first results of the Cohort Study are anticipated in Q1 2017.

“The Cohort Study will use ProMIS’s five recently validated monoclonal antibodies (mAbs) to detect specific prion targets (epitopes) in samples from AD patients,” stated ProMIS CSO Dr. Neil Cashman. “To our knowledge, this is the first program aimed at generating a broad dataset to assess the prevalence of different Aß prion strains in AD patients”.

The Cohort Study is being conducted in the laboratories of ProMIS CSO, Dr. Neil Cashman. The study will use cerebrospinal fluid (CSF) samples from more than 100 patients with dementia, collected over an eight-year period by Dr. Robin Hsiung, Associate Professor of Neurology at the University of British Columbia. The detailed clinical and laboratory data accompanying some of the samples may also lead to the identification of prion strains associated with more rapid disease progression and/or more prevalent in certain patient subgroups.

“This revolutionary Cohort Study may provide important evidence supporting a critical role for our antibodies in AD”, stated ProMIS Executive Chairman, Eugene Williams. “First, detection of prion targets in CSF samples using our specific mAbs may not only allow to confirm diagnosis of AD but also to determine what subgroup of AD is present, based on which Aß prion targets are detected. Second, these mAbs, after humanization and scale-up, could offer the greatest chance for effective treatment specifically targeted to these subgroups of AD patients, and ultimately may lead to their use for prevention of disease”.

As results of the Cohort Study emerge, the Company plans to pursue multiple research collaborations to further support its precision medicine approach to AD. ProMIS is also evaluating the feasibility and development of a blood-based detection method, which would enable broad screening of patients at risk or suspected of having AD.

Commenting on the Company’s program, Mara Aspinall, a recognized expert in precision medicine and member of the ProMIS Business Advisory Board, stated: “Alzheimer’s Disease has all the hallmarks for the next breakthrough in personalized medicine – a complex disease with variable presentation and prognosis. ProMIS insights and anticipated outcomes of the Cohort Study could represent an important, fundamental shift in our approach to precision diagnosis and treatment of AD”.

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences aims to develop novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS.

The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:
http://www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

NATIONAL Equicom
Michael Moore                 Abby Garfunkel
Tel. 858-886-7813             Tel. 403-218-2887
mmoore(at)national.ca        agarfunkel(at)national.ca

or contact

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com

Read the full story at http://www.prweb.com/releases/2016/11/prweb13826773.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. Are probiotics a promising treatment strategy for depression?
2. Nanotech researchers 2-step method shows promise in fighting pancreatic cancer
3. Drug offers promising approach to improve outcome for children with high-risk leukemia
4. Drug Offers Promising Approach to Improve Outcome for Children with High-risk Leukemia
5. Drug shows early promise in treating seizures
6. GUMBOS promise new drugs and electronics: American Chemical Society Prized Science video
7. New research shows promise for possible HIV cure
8. Pediatric infectious disease chief authors new vaccination guideline for immunocompromised patients
9. Cohen Pediatric Infectious Disease Chief Authors New Vaccination Guideline for Immunocompromised Patients
10. Promising results for Swedish cancer drug candidate
11. Promising Alzheimers drug trialled in a large EU study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... MD Now’s 28th facility overall and marks the urgent care center's eighth location in ... North of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an upcoming episode ... Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for more info. ... 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in science and ...
(Date:6/23/2017)... Chicago, IL (PRWEB) , ... June 23, 2017 ... ... insurance management assistance and financial planning services to communities in the greater Chicago ... Children’s Association to offer assistance to underprivileged youth in Chicago. , Founded in ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... is pleased to welcome Whipple & Company as its newest Partner Firm. Headquartered ... of balancing their clients’ risk while tailoring optimized benefit packages that strengthen the ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: